Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series</title>
<author><name sortKey="Tsang, D S" sort="Tsang, D S" uniqKey="Tsang D" first="D. S." last="Tsang">D. S. Tsang</name>
<affiliation><nlm:aff id="af1-conc-23-e630">Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Le, L W" sort="Le, L W" uniqKey="Le L" first="L. W." last="Le">L. W. Le</name>
<affiliation><nlm:aff wicri:cut="; and" id="af2-conc-23-e630">Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kukreti, V" sort="Kukreti, V" uniqKey="Kukreti V" first="V." last="Kukreti">V. Kukreti</name>
<affiliation><nlm:aff id="af3-conc-23-e630">Division of Hematology/Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sun, A" sort="Sun, A" uniqKey="Sun A" first="A." last="Sun">A. Sun</name>
<affiliation><nlm:aff id="af1-conc-23-e630">Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">28050154</idno>
<idno type="pmc">5176391</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176391</idno>
<idno type="RBID">PMC:5176391</idno>
<idno type="doi">10.3747/co.23.3288</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">002028</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002028</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series</title>
<author><name sortKey="Tsang, D S" sort="Tsang, D S" uniqKey="Tsang D" first="D. S." last="Tsang">D. S. Tsang</name>
<affiliation><nlm:aff id="af1-conc-23-e630">Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Le, L W" sort="Le, L W" uniqKey="Le L" first="L. W." last="Le">L. W. Le</name>
<affiliation><nlm:aff wicri:cut="; and" id="af2-conc-23-e630">Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kukreti, V" sort="Kukreti, V" uniqKey="Kukreti V" first="V." last="Kukreti">V. Kukreti</name>
<affiliation><nlm:aff id="af3-conc-23-e630">Division of Hematology/Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sun, A" sort="Sun, A" uniqKey="Sun A" first="A." last="Sun">A. Sun</name>
<affiliation><nlm:aff id="af1-conc-23-e630">Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Current Oncology</title>
<idno type="ISSN">1198-0052</idno>
<idno type="eISSN">1718-7729</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background</title>
<p>Primary cutaneous plasmacytoma (p<sc>cp</sc>
) is a rare disease, with few studies to guide therapy. Our primary study objective was to define treatments used for p<sc>cp</sc>
; a secondary objective was to describe outcomes of patients, including disease recurrence and death.</p>
</sec>
<sec><title>Methods</title>
<p>An institutional cancer registry was used to identify cases for retrospective chart review. In a systematic review, treatments for, and outcomes of, all known cases of p<sc>cp</sc>
were described.</p>
</sec>
<sec><title>Results</title>
<p>Three eligible cases identified at our institution; each patient had a solitary p<sc>cp</sc>
. The systematic review identified 66 patients. Radiotherapy was the most commonly used primary treatment modality (31% of all patients; 42% for patients with solitary lesions), followed by surgery (28% of all patients; 36% for patients with solitary lesions). Median survival for all patients was 10.4 years [95% <sc>ci</sc>
: 4.3 years to not reached], with a trend toward a decreased risk of death with solitary lesions compared with multiple lesions (hazard ratio: 0.37; 95% <sc>ci</sc>
: 0.13 to 1.08; <italic>p</italic>
= 0.059). For patients with solitary lesions, the median and recurrence-free survivals were, respectively, 17.0 years (95% <sc>ci</sc>
: 1.7 years to not reached) and 11.0 years (95% <sc>ci</sc>
: 2 years to not reached); for patients with multiple lesions, they were 4.3 years (95% <sc>ci</sc>
: 1.3 to not reached) and 1.4 years (95% <sc>ci</sc>
: 0.6 years to not reached). Disease recurrence, including progression to multiple myeloma, was the most common cause of death.</p>
</sec>
<sec><title>Conclusions</title>
<p>Compared with patients having multiple p<sc>cp</sc>
lesions, those presenting with a single p<sc>cp</sc>
lesion might experience longer overall survival. Local therapy (radiation or surgery) is a reasonable curative treatment for a solitary p<sc>cp</sc>
lesion.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="case-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id>
<journal-id journal-id-type="publisher-id">CO</journal-id>
<journal-title-group><journal-title>Current Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1198-0052</issn>
<issn pub-type="epub">1718-7729</issn>
<publisher><publisher-name>Multimed Inc.</publisher-name>
<publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">28050154</article-id>
<article-id pub-id-type="pmc">5176391</article-id>
<article-id pub-id-type="doi">10.3747/co.23.3288</article-id>
<article-id pub-id-type="publisher-id">conc-23-e630</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group><article-title>Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Tsang</surname>
<given-names>D.S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-conc-23-e630"><sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Le</surname>
<given-names>L.W.</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="af2-conc-23-e630"><sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kukreti</surname>
<given-names>V.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af3-conc-23-e630"><sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sun</surname>
<given-names>A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-conc-23-e630"><sup>*</sup>
</xref>
<xref ref-type="corresp" rid="c1-conc-23-e630"></xref>
</contrib>
<aff id="af1-conc-23-e630"><label>*</label>
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;</aff>
<aff id="af2-conc-23-e630"><label>†</label>
Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network; and</aff>
<aff id="af3-conc-23-e630"><label>‡</label>
Division of Hematology/Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON.</aff>
</contrib-group>
<author-notes><corresp id="c1-conc-23-e630">Correspondence to: Alexander Sun, Department of Radiation Oncology, 610 University Avenue, Toronto, Ontario M5G 2M9. E-mail: <email>alex.sun@rmp.uhn.on.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub"><day>21</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<issue>6</issue>
<fpage>e630</fpage>
<lpage>e646</lpage>
<permissions><copyright-statement>2016 Multimed Inc.</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract><sec><title>Background</title>
<p>Primary cutaneous plasmacytoma (p<sc>cp</sc>
) is a rare disease, with few studies to guide therapy. Our primary study objective was to define treatments used for p<sc>cp</sc>
; a secondary objective was to describe outcomes of patients, including disease recurrence and death.</p>
</sec>
<sec><title>Methods</title>
<p>An institutional cancer registry was used to identify cases for retrospective chart review. In a systematic review, treatments for, and outcomes of, all known cases of p<sc>cp</sc>
were described.</p>
</sec>
<sec><title>Results</title>
<p>Three eligible cases identified at our institution; each patient had a solitary p<sc>cp</sc>
. The systematic review identified 66 patients. Radiotherapy was the most commonly used primary treatment modality (31% of all patients; 42% for patients with solitary lesions), followed by surgery (28% of all patients; 36% for patients with solitary lesions). Median survival for all patients was 10.4 years [95% <sc>ci</sc>
: 4.3 years to not reached], with a trend toward a decreased risk of death with solitary lesions compared with multiple lesions (hazard ratio: 0.37; 95% <sc>ci</sc>
: 0.13 to 1.08; <italic>p</italic>
= 0.059). For patients with solitary lesions, the median and recurrence-free survivals were, respectively, 17.0 years (95% <sc>ci</sc>
: 1.7 years to not reached) and 11.0 years (95% <sc>ci</sc>
: 2 years to not reached); for patients with multiple lesions, they were 4.3 years (95% <sc>ci</sc>
: 1.3 to not reached) and 1.4 years (95% <sc>ci</sc>
: 0.6 years to not reached). Disease recurrence, including progression to multiple myeloma, was the most common cause of death.</p>
</sec>
<sec><title>Conclusions</title>
<p>Compared with patients having multiple p<sc>cp</sc>
lesions, those presenting with a single p<sc>cp</sc>
lesion might experience longer overall survival. Local therapy (radiation or surgery) is a reasonable curative treatment for a solitary p<sc>cp</sc>
lesion.</p>
</sec>
</abstract>
<kwd-group><kwd>Chemotherapy</kwd>
<kwd>plasmacytoma</kwd>
<kwd>radiotherapy</kwd>
<kwd>skin</kwd>
<kwd>surgery</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002028 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002028 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
This area was generated with Dilib version V0.6.31. |